Frederik Jacob Estrup

Partner (Copenhagen)
Dir. +45 38 77 46 10
Mob. +45 20 19 74 85

Frederik Jacob Estrup specialises in business transfers and investments (M&A), capital market law, and company and foundation law and has a particular focus on private equity funds.

Frederik assists clients in both Denmark and abroad in connection with their M&A activities. Over the years, he has guided Danish and foreign private equity funds through complex investments and restructurings.

Frederik also has detailed knowledge of incentive programmes, W&I insurance and regulation of shareholder issues. In addition, he has assisted in numerous transfers of software companies.     

Frederik always seeks to offer clients to-the-point advice, focusing not only on their legal, but also on their commercial interests. 

Frederik is also Kromann Reumert’s knowledge ambassador in the field of M&A. As such, he is responsible for providing M&A training to our assistant and junior attorneys.

Background

Career

  • Partner, Kromann Reumert, 2023-
  • Director, Kromann Reumert, 2021-2022
  • Kirkland & Ellis LLP (New York), secondment, 2017-2018
  • Kromann Reumert, 2012-
     

Education

  • Admitted to practise law 2015
  • Master of Laws (cand. jur.), University of Copenhagen, 2012
  • Duke University School of Law, North Carolina (US), 2010
     

Languages

  • Danish
  • English

High-profile cases

Frederik has assisted clients in a vast number of transactions, including the following:

  • Axcel’s acquisition of NTI Group (2022)
  • Axcel’s acquisition of  ITM8 (2022)
  • Majority sellers’ sale of Polar Seafood Denmark (2022)
  • SAS Cargo’s sale of Trust Forwarding business (2022)
  • Via Equity’s platform investments into Struct and Decision Focus (2022)
  • Triton’s acquisition of Geia Food (2021)
  • Lone Star Funds in connection with their sale of Stark Gruppen to CVC Capital Partners (2020)
  • Volpi Capital in connection with their acquisition of Boyum IT Solutions (2020)
  • Nordic Capital in connection with their acquisition of Conscia (2019)
  • Genmab in connection with their listing of ADRs on Nasdaq Global Select US (2019)

Documents

Download CV